These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Baicalein exerts anti-neuroinflammatory effects to protect against rotenone-induced brain injury in rats. Zhang X; Yang Y; Du L; Zhang W; Du G Int Immunopharmacol; 2017 Sep; 50():38-47. PubMed ID: 28623717 [TBL] [Abstract][Full Text] [Related]
23. Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide? Fothergill-Misbah N; Maroo H; Cham M; Pezzoli G; Walker R; Cilia R Parkinsonism Relat Disord; 2020 Apr; 73():3-7. PubMed ID: 32179240 [TBL] [Abstract][Full Text] [Related]
24. Analysis of Levodopa Content in Commercial Mucuna pruriens Products Using High-Performance Liquid Chromatography with Fluorescence Detection. Soumyanath A; Denne T; Hiller A; Ramachandran S; Shinto L J Altern Complement Med; 2018 Feb; 24(2):182-186. PubMed ID: 28922612 [TBL] [Abstract][Full Text] [Related]
26. Antiparkinson drug--Mucuna pruriens shows antioxidant and metal chelating activity. Dhanasekaran M; Tharakan B; Manyam BV Phytother Res; 2008 Jan; 22(1):6-11. PubMed ID: 18064727 [TBL] [Abstract][Full Text] [Related]
27. Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. Palmas MF; Ena A; Burgaletto C; Casu MA; Cantarella G; Carboni E; Etzi M; De Simone A; Fusco G; Cardia MC; Lai F; Picci L; Tweedie D; Scerba MT; Coroneo V; Bernardini R; Greig NH; Pisanu A; Carta AR Neurotherapeutics; 2022 Jan; 19(1):305-324. PubMed ID: 35072912 [TBL] [Abstract][Full Text] [Related]
28. Recovery of motor function is associated with rescue of glutamate biomarkers in the striatum and motor cortex following treatment with Mucuna pruriens in a murine model of Parkinsons disease. Denne T; Winfrey LC; Moore C; Whitner C; D'Silva T; Soumyanath A; Shinto L; Hiller A; Meshul CK Mol Cell Neurosci; 2023 Sep; 126():103883. PubMed ID: 37527694 [TBL] [Abstract][Full Text] [Related]
29. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881 [TBL] [Abstract][Full Text] [Related]
30. Seed extract of Thai Mucuna pruriens (L.) DC. var. pruriens enhances sexual performance and improves male reproductive damages in ethanol-induced rats. Tangsrisakda N; Kamollerd T; Taoto C; Bunsueb S; Chaimontri C; Choowong-In P; Lapyuneyong N; Wu AT; Thukhammee W; Wattanathorn J; Arun S; Sawatpanich T; Iamsaard S J Ethnopharmacol; 2022 Jun; 292():115219. PubMed ID: 35339625 [TBL] [Abstract][Full Text] [Related]
31. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra. Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869 [TBL] [Abstract][Full Text] [Related]
32. Enhanced Physicochemical Stability of the L-DOPA Extract of Vilairat C; Kobtrakul K; Vimolmangkang S Molecules; 2023 Feb; 28(4):. PubMed ID: 36838562 [TBL] [Abstract][Full Text] [Related]
33. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Manyam BV; Dhanasekaran M; Hare TA Phytother Res; 2004 Feb; 18(2):97-101. PubMed ID: 15022157 [TBL] [Abstract][Full Text] [Related]
34. Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report. Radder DLM; Tiel Groenestege AT; Boers I; Muilwijk EW; Bloem BR J Parkinsons Dis; 2019; 9(2):437-439. PubMed ID: 30856121 [TBL] [Abstract][Full Text] [Related]
35. Effects of the hydroethanolic extract of Mucuna pruriens (L.) DC (Fabaceae) on haematological profile in normal and haloperidol treated rats. Akindele AJ; Busayo FI Nig Q J Hosp Med; 2011; 21(2):93-8. PubMed ID: 21913505 [TBL] [Abstract][Full Text] [Related]
36. Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease. Jang H; Kim S; Lee JM; Oh YS; Park SM; Kim SR Neuroreport; 2017 Mar; 28(5):242-249. PubMed ID: 28178069 [TBL] [Abstract][Full Text] [Related]
37. Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines. Alam Q; Alam MZ; Mushtaq G; Damanhouri GA; Rasool M; Kamal MA; Haque A Curr Pharm Des; 2016; 22(5):541-8. PubMed ID: 26601965 [TBL] [Abstract][Full Text] [Related]
38. Attenuation of neuroinflammatory responses and behavioral deficits by Ligusticum officinale (Makino) Kitag in stimulated microglia and MPTP-induced mouse model of Parkinson's disease. Kim BW; Koppula S; Park SY; Kim YS; Park PJ; Lim JH; Kim IS; Choi DK J Ethnopharmacol; 2015 Apr; 164():388-97. PubMed ID: 25449453 [TBL] [Abstract][Full Text] [Related]
39. 6-Shogaol, a ginger product, modulates neuroinflammation: a new approach to neuroprotection. Ha SK; Moon E; Ju MS; Kim DH; Ryu JH; Oh MS; Kim SY Neuropharmacology; 2012 Aug; 63(2):211-23. PubMed ID: 22465818 [TBL] [Abstract][Full Text] [Related]
40. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Rathi SS; Grover JK; Vats V Phytother Res; 2002 May; 16(3):236-43. PubMed ID: 12164268 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]